Periplogenin induces necroptotic cell death through oxidative stress in HaCaT cells and ameliorates skin lesions in the TPA- and IMQ-induced psoriasis-like mouse models

Biochem Pharmacol. 2016 Apr 1:105:66-79. doi: 10.1016/j.bcp.2016.02.001. Epub 2016 Feb 3.

Abstract

Psoriasis is a multifactorial skin disease that inconveniences many patients. Considering the side effects and drug resistance of the current therapy, it is urgent to discover more effective and safer anti-psoriatic drugs. In the present study, we screened over 250 traditional Chinese medicine compounds for their ability to inhibit the cell viability of cultured human HaCaT keratinocytes, a psoriasis-relevant in vitro model, and found that periplogenin was highly effective. Mechanistic studies revealed that apoptosis and autophagy were not induced by periplogenin in HaCaT cells. However, periplogenin caused PI to permeate into cells, increased lactate LDH release and rapidly increased the number of necrotic cells. Additionally, the typical characteristics of necrosis were observed in the periplogenin-treated HaCaT cells. Notably, the necroptosis inhibitor Nec-1 and NSA were able to rescue the cells from necrotic cell death, supporting that necroptosis was involved in periplogenin-induced cell death. Furthermore, the ROS levels were elevated in the periplogenin-treated cells, NAC (an antioxidant) and Nec-1 could inhibit the ROS levels, and NAC could attenuate necroptotic cell death, indicating that the periplogenin-induced necroptotic cell death was mediated by oxidative stress. More importantly, in the murine models of TPA-induced epidermal hyperplasia and IMQ-induced skin inflammation, topical administration of periplogenin ameliorated skin lesions and inflammation. In sum, our results indicate, for the first time, that periplogenin is a naturally occurring compound with potent anti-psoriatic effects in vitro and in vivo, making it a promising candidate for future drug research.

Keywords: 3-MA (PubChem CID: 1673); CQ (PubChem CID: 64927); IMQ (PubChem CID: 57469); LY294002 (PubChem CID: 3973); NAC (PubChem CID: 12035); NSA (PubChem CID: 1566236); Nec-1 (PubChem CID: 2828334); Necroptosis; Periplogenin; Periplogenin (PubChem CID: 10574); Psoriasis; ROS; TPA (PubChem CID: 27924); z-VAD-fmk (PubChem CID: 5497173).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminoquinolines / toxicity*
  • Animals
  • Cell Death / drug effects
  • Cell Death / physiology
  • Cell Line
  • Cell Survival / drug effects
  • Cell Survival / physiology
  • Digitoxigenin / analogs & derivatives*
  • Digitoxigenin / pharmacology
  • Digitoxigenin / therapeutic use
  • Disease Models, Animal*
  • Female
  • Humans
  • Imiquimod
  • Mice
  • Mice, Inbred BALB C
  • Necrosis / chemically induced
  • Necrosis / drug therapy
  • Necrosis / metabolism
  • Oxidative Stress / drug effects
  • Oxidative Stress / physiology*
  • Psoriasis / chemically induced
  • Psoriasis / drug therapy
  • Psoriasis / metabolism*
  • Tetradecanoylphorbol Acetate / toxicity*

Substances

  • Aminoquinolines
  • Digitoxigenin
  • periplogenin
  • Tetradecanoylphorbol Acetate
  • Imiquimod